Posts Tagged ‘common cold’
Update on Nasodine Phase 3 trial
02 Nov 2022
Firebrick Pharma is pleased to provide an update on our Phase 3 clinical trial of Nasodine® Nasal Spray in the treatment of the common cold. As at 31 October, the trial has so far successfully recruited 224 subjects with early-stage colds into the ITT (‘Intent-To-Treat’ population), with an estimated 100 qualifying for the primary endpoint…
Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine
17 May 2022
Firebrick Pharma’s Dr Peter Molloy and Dr Chris Rock from CMAX Clinical Research discuss with Channel 7 the start of our Phase 3 common cold trial for Nasodine® Nasal Spray. Adelaide is the first location for the trial, with sites in Victoria and South Africa to follow. If you live in South Australia or Victoria,…